Group items tagged

Global drug discovery services market will continue to grow, owing to upsurge in externalization of R&D activities, rising expenditure on R&D, and increasing incidence of chronic diseases. Expiration of patents boosting the demand for drug discovery and the introduction of innovative drug discovery technologies are projected to support the market growth during the forecast period 2019-2025. The global drug discovery services market, by type, is segmented into medicinal chemistry services, biology services, and pharmacokinetics and drug metabolism. Among these, the medicinal chemistry services segment accounted for the largest share in 2018 and is expected to grow at a high-double-digit CAGR by 2025. Increasing tendency of pharma companies to externalize discovery & development services, upsurge in the number of drug discovery & development activities, and growing R&D expenditure are the key factors driving the growth of the segment.

the "Global Lung Cancer Drugs Market" will grow at a CAGR of 13.6% during the forecast period. The market has witnessed steady growth in the past few years with the introduction of novel products, which have augmented the acceptance of immunotherapy drugs in the market. The market is fueled by upsurge in the incidence of lung cancer cases across the globe - owing to increasing diagnosis rate and mainly due to increasing tobacco consumption, increase in the lung cancer treatment rates, increasing rate of effective drug approvals as first-line therapies, strategic deals to develop new products, increasing R&D spending, and rapid industrialization leading to increased pollution. The report provides complete details about the sub-segments of the lung cancer drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, and government initiatives towards the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market.

The global immunotherapy drugs market will continue to grow, owing to increasing incidence of lifestyle-related and chronic disease globally, increasing product approvals, rising healthcare expenditures, and increasing access to better diagnostic & treatment facilities. High preference for immunotherapy over traditional chemotherapy and its use in combination with the same in first-line treatments coupled with high adoption of targeted therapies is expected to support the market growth during the forecast period 2019-2025. The immunotherapy drugs market, by type of drug, is segmented into monoclonal antibodies (mAbs), vaccine, non-specific immunotherapies, adaptive cell therapy, and others. Among these, monoclonal antibodies occupied a significant share in 2018 while the fastest growing type was adaptive cell therapy, which is expected to grow at a high CAGR during the forecast period 2019-2025. Increased preference for mAbs with fewer side-effects made this type the dominant market shareholder in 2018.

The global market for chronic kidney disease drugs is expected to witness single-digit growth during 2019-2025. The drug pipeline of chronic kidney disease looks promising with novel therapeutic approaches, such as cell therapy, likely to enhance the market growth opportunities. However, the competition from biosimilars and complex drug development processes are impeding the market growth. Over the period, extensive research is being done to fill the unmet needs' gap. The advances in the arena of regenerative treatment have come up with budding advancement of cell therapies that help regeneration and repairing of the kidneys. Cell therapy is proficient of refining the fundamental functioning capability of the kidney. Uncontrolled high blood pressure and diabetes are the leading causes of kidney failure globally.

North America leads the global heart failure drugs market in 2018 followed by Europe. The US dominates the market owing to the presence of a majority of the heart failure drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the presence of large heart failure patient population and availability of wide range of drugs. Most of the revenue is generated from the leading players in the market with dominant sales from Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, Bayer AG, and Pfizer Inc.

Companion diagnostics is a clinically established diagnostic tool used in conjunction with a therapeutic agent to identify the applicability of that drug to an individual patient. Companion diagnosis is generally the last step of drug management and usually involves a process of screening, evaluating, and prescribing medication based on the findings of companion diagnostics. A companion diagnose determines whether a particular drug therapy is suitable for the patient in terms of safety, toleration, and response to treatment. It is basically an advanced form of drug management that focuses on evaluating and implementing personalized treatment plans based on known medical issues and considerations. Increasing prevalence of cancer is expected to propel growth of the global companion diagnostics market over the forecast period. For instance, according to the American Cancer Society, in 2020, around 276,480 new cases of invasive breast cancer will be diagnosed in women and the disease will lead to around 42,170 deaths, in the U.S. Moreover, increasing development and commercialization of new products is also expected to aid in growth of the market. For instance, in November 2020, LabCorp announced an expanded agreement with BML, a leading Japanese provider of clinical laboratory testing services, to provide development and delivery of companion diagnostics in Japan. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/increasing-prevalence-of-cancer-and.html

How chemotherapy takes place? Depending on type of cancer and period of cancer, it stops cancer cells ability of damage and more to divide. Oftenly drugs are used and different for different person. This is systematic therapy also affect your entire body.

Study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.

study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.

3D printing solutions provider Materialise has obtained clearance for its Mimics Enlight cardiovascular planning software suite from the US Food and Drug Administration (FDA).

MedGenome is the only genetic diagnostics lab in India which is CAP accredited for Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES).

Electronic Medical Records: ProviNET is about halfway through a three-year process to implement an EMR from HealthMEDX to support physician order entry, nurse notes, documentation by certified nursing assistants (CNAs) and e-prescribing. On the long-term care side, the organization is implementing one EMR component at a time and expects to implement the last component-e-prescribing-in about a year, once the new standards from the National Council for Prescription Drug Programs can be tested. On the home and community-based service side, ProviNET has completed its EMR implementation.

Tynor Hot and Cold Pack is a convenient device to provide hot fomentation or cold compress. Hot fomentation of the injured or inflamed area enhances the threshold of pain and thus reduces the perception of pain. It has a synergistic effect along with pain relieving drugs. Raising temperature of the injured tissue also enhances the blood profusion and the healing process. Hot fomentation has a relaxing effect. Cold compress helps in reduction of inflammation in injuries, protects by slowing the metabolic rate around the tissue, reduce oedema and bleeding. Cold compress helps in immediately lowering fever, in very high fever conditions. It can be used after an acute injury or surgical procedure. No heat or cryo burns. Requires no holding. Reusable. Easy application. Appealing aesthetics. Tynor Hot and Cold Pack Features Multi functionality Reduce swelling and odema at the site of injury. Muscles spasm and pain. Headache and minor injuries. Versatile design Can be used as either cold or hot pack. Reusable in either hot & cold condition. Temperature range - Can be used from 0 Cº to 75Cº. Longer temperature retention time. Fabric cover ensures no cryo burns or hot skin burns. Physical features Non-toxic, and biodegradable. Gel remains soft and flexible upto 0 degree. Durable, and puncture resistant. Soft, "frost free" PVC cover. Flexible conforms to the body contours. Easy to clean and maintain. Excellent workmanship. Good aesthetics. Elastic belt Holds the pack against the body, No need to hold by hand. Enhances convenience. Tynor Hot and Cold Pack Measurements